Tirzepatide: Research overview, identity, and laboratory handling guide

Synthetic dual GLP-1 / GIP receptor agonist studied in vitro for combination incretin-pathway research. ≥99% HPLC. Research use only. This guide covers identity, published research context, procurement checks, and storage — RUO only, no clinical claims.

What Tirzepatide is in published research

Tirzepatide is a 39-amino-acid synthetic peptide engineered as a dual agonist at GIPR and GLP-1R, carrying a C20 di-acid fatty-acid modification for extended pharmacokinetics in published research models. The peptide is studied in vitro for cAMP signaling at GIPR vs GLP-1R, downstream β-cell line responses, and combination metabolic pathway work.

Each lot ships with ≥99% HPLC purity, MS identity verification covering backbone and acyl-group, and net peptide content on the CoA.

Hold lyophilized vials at -20 °C in original packaging away from light. Reconstitute in lab-grade slightly alkaline buffer; aliquot before freezing.

CoA + lot batch records on file by SKU.

The material class "GLP-1 / GIP dual agonist (research)" helps procurement teams group Tirzepatide with related reference peptides during comparative studies.

Sequence and identity

Tirzepatide identity on the catalog: Common name: Tirzepatide (LY3298176); Class: GLP-1 / GIP dual receptor agonist, acylated; Molecular formula: C225H348N48O68; Molecular weight: 4,813.45 g/mol; Appearance: White lyophilized powder; Purity (HPLC): ≥ 99%; Solubility: Soluble in slightly alkaline lab buffers. Copy these into receiving and LIMS before reconstitution.

Mechanisms studied in published research

Mechanism-focused research on Tirzepatide is typically conducted in cell lines or biochemical preparations that express the relevant receptor or binding protein for its class.

Design controls that include scrambled-sequence or orthogonal-receptor negative controls when your protocol evaluates Tirzepatide pharmacology in vitro.

Report effect sizes with lot number and CoA reference so results can be reproduced if the same Tirzepatide SKU is reordered later.

Avoid extrapolating in vitro binding or signaling readouts to whole-organism outcomes; RUO materials are not qualified for clinical investigation.

Procurement and identity verification

Request the lot-specific CoA for Tirzepatide at receipt. Verify SKU, variant size if applicable, and identity mass before the lot enters general storage.

Compare HPLC purity to your internal minimum for the peptide family. File chromatogram excerpts when your QMS requires raw data.

Enter net peptide content from the CoA into inventory before calculating molarity for Tirzepatide working stocks.

Attach purchase order, packing list, and CoA in one audit folder per lot.

Storage and reconstitution

Store lyophilized Tirzepatide sealed at -20 °C protected from light unless the CoA states otherwise.

Reconstitute with bacteriostatic water or a buffer validated for your assay pH. Aliquot to limit freeze-thaw.

For oxidation-sensitive sequences in Tirzepatide, minimize open-vial time at room temperature during weighing.

See our lyophilized storage guide for institution-scale SOP examples and aliquot labeling conventions.

Comparative reference points

Researchers comparing Tirzepatide with adjacent catalog references often evaluate the following SKUs in parallel plates:

Use matched reconstitution buffers and stock concentrations when running comparative binding or signaling assays.

Document reviewers should cross-link this guide with the product certificate of analysis and internal receiving SOP.

When publishing methods, cite lot number, SKU, reconstitution buffer, and stock concentration so external labs can interpret your figures.

Institutional procurement may require RUO acknowledgment at checkout; store that acknowledgment beside batch records for audits.

If assay results drift across quarters, compare storage logs and CoA revision before questioning sequence integrity.

Third-party summaries, when available, should be filed as supplements—not replacements—for CoA identity data.

Document reviewers should cross-link this guide with the product certificate of analysis and internal receiving SOP.

When publishing methods, cite lot number, SKU, reconstitution buffer, and stock concentration so external labs can interpret your figures.

Institutional procurement may require RUO acknowledgment at checkout; store that acknowledgment beside batch records for audits.

If assay results drift across quarters, compare storage logs and CoA revision before questioning sequence integrity.

Third-party summaries, when available, should be filed as supplements—not replacements—for CoA identity data.

Document reviewers should cross-link this guide with the product certificate of analysis and internal receiving SOP.

When publishing methods, cite lot number, SKU, reconstitution buffer, and stock concentration so external labs can interpret your figures.

Institutional procurement may require RUO acknowledgment at checkout; store that acknowledgment beside batch records for audits.

If assay results drift across quarters, compare storage logs and CoA revision before questioning sequence integrity.

Third-party summaries, when available, should be filed as supplements—not replacements—for CoA identity data.

Document reviewers should cross-link this guide with the product certificate of analysis and internal receiving SOP.

When publishing methods, cite lot number, SKU, reconstitution buffer, and stock concentration so external labs can interpret your figures.

Institutional procurement may require RUO acknowledgment at checkout; store that acknowledgment beside batch records for audits.

If assay results drift across quarters, compare storage logs and CoA revision before questioning sequence integrity.

Third-party summaries, when available, should be filed as supplements—not replacements—for CoA identity data.

Document reviewers should cross-link this guide with the product certificate of analysis and internal receiving SOP.

When publishing methods, cite lot number, SKU, reconstitution buffer, and stock concentration so external labs can interpret your figures.

Institutional procurement may require RUO acknowledgment at checkout; store that acknowledgment beside batch records for audits.

If assay results drift across quarters, compare storage logs and CoA revision before questioning sequence integrity.

Third-party summaries, when available, should be filed as supplements—not replacements—for CoA identity data.

Document reviewers should cross-link this guide with the product certificate of analysis and internal receiving SOP.

When publishing methods, cite lot number, SKU, reconstitution buffer, and stock concentration so external labs can interpret your figures.

Institutional procurement may require RUO acknowledgment at checkout; store that acknowledgment beside batch records for audits.

If assay results drift across quarters, compare storage logs and CoA revision before questioning sequence integrity.

Third-party summaries, when available, should be filed as supplements—not replacements—for CoA identity data.

Document reviewers should cross-link this guide with the product certificate of analysis and internal receiving SOP.

When publishing methods, cite lot number, SKU, reconstitution buffer, and stock concentration so external labs can interpret your figures.

Institutional procurement may require RUO acknowledgment at checkout; store that acknowledgment beside batch records for audits.

If assay results drift across quarters, compare storage logs and CoA revision before questioning sequence integrity.

Third-party summaries, when available, should be filed as supplements—not replacements—for CoA identity data.

Document reviewers should cross-link this guide with the product certificate of analysis and internal receiving SOP.

When publishing methods, cite lot number, SKU, reconstitution buffer, and stock concentration so external labs can interpret your figures.

Institutional procurement may require RUO acknowledgment at checkout; store that acknowledgment beside batch records for audits.

If assay results drift across quarters, compare storage logs and CoA revision before questioning sequence integrity.

Third-party summaries, when available, should be filed as supplements—not replacements—for CoA identity data.